media – Page 19 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Zelgen Biopharma’s Drug-in-Development Sold for Over $1.2 Billion

Cailian Press, December 31 (Reporter: Wu Chao) – Another Chinese pharmaceutical firm has secured a major overseas Business Development (BD) deal exceeding $1 billion for a DLL3-targeted drug. Zelgen Biopharma (688266.SH) has reached an agreement with a global pharmaceutical giant for the worldwide development and commercialization of its core pipeline product, ZG006 (Alveltamig), with a potential total value surpassing $1.2 billion. Zelgen Biopharma announced this evening that it has entered into a strategic collaboration and license option agreement with a holding company of the AbbVie Group (registered in Bermuda, hereinafter “AbbVie”) regarding ZG006. Under the terms, AbbVie will obtain exclusive rights to develop and commercialize ZG006 outside of Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), while Zelgen retains all rights within the Greater China region. According to the agreement, Zelgen will receive an upfront payment of $100 million, plus near-term clinical milestone payments and license-option-related payments of ...
- Source: drugdu
- 91
- January 4, 2026
Rongchang Bio’s “Vidicituzumab” is proposed to be included in the Breakthrough Therapy list for a new indication

On December 31, the CDE website showed that Rongchang Bio’s vidicetuzumab is proposed to be included in the Breakthrough Therapy list for a new indication, in combination with trastuzumab and toripalimab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression . Vidicetumab has been included in the Breakthrough Therapy designation three times before . If it passes the public announcement this time, it will become the drug’s fourth Breakthrough Therapy designation . Vidicetumab is a HER2-targeted ADC drug developed by Rongchang Biotechnology. Through a “precision burst” mechanism, it can not only kill HER2-highly expressing tumor cells, but also attack neighboring HER2-low-expressing cells through the “bystander effect.” Since its initial approval in 2021, this product has been approved for three indications : HER2-overexpressing locally advanced or metastatic gastric cancer that has received at least two types of systemic chemotherapy ; Patients with previously received systemic chemotherapy and HER2-overexpressing ...
- Source: drugdu
- 81
- January 4, 2026
Xingmeng Biotech obtains its first international GMP certification, accelerating the global rollout of its innovative monoclonal antibody drug, Cribi®.

On December 31, 2025, Xingmeng Biopharmaceutical (Suzhou) Co., Ltd. (“Xingmeng Biopharmaceutical”) announced that it had officially obtained the Good Manufacturing Practice (GMP) certificate for pharmaceuticals issued by the Turkish Pharmaceutical and Medical Devices Authority (TITCK) . This certification is not only Xingmeng Biopharmaceutical’s first overseas GMP certificate , but also signifies that the production quality management system of its independently developed core product, Zamerovic-Mazoprevir Injection (trade name: Cribi®), has reached international standards, obtaining key qualifications for this innovative product to enter the mainstream global market. The official GMP compliance on-site inspection by the Turkish authorities was conducted from September 15th to 19th, 2025. Following a rigorous audit, TITCK announced at the closing meeting that the Xingmeng Suzhou production base had achieved the highest level of compliance, “Class I.” According to procedure, TITCK officially issued the GMP certificate on December 18th, 2025. Image: GMP certificate issued by the Turkish Medicines and ...
- Source: drugdu
- 77
- January 4, 2026
The battle between Novo Nordisk and Eli Lilly for market dominance is spreading eastward

In recent years, the weight-loss drug market has been primarily focused on the United States and Europe , revolving around price, affordability, health insurance negotiations, and market penetration caps. However, with several GLP-1 drugs completing their initial market rollout in major global markets, competition is extending to new variables. Against this backdrop, India has gradually come into focus . Competition surrounding the Indian market has become continuous and traceable, making Eli Lilly and Novo Nordisk’s strategies in this market a key point to watch in the 2026 weight-loss drug competition. 01 Ozempic launches in India. The pricing standards are intriguing. Novo Nordisk recently launched Ozempic in India and announced the full dosage gradient and monthly pricing at the same time . Specifically, Ozempic is available in India in three strengths: 0.25 mg, 0.5 mg, and 1 mg, all as pre-filled syringes; the monthly prices are 8,800 rupees ($98), 10,170 rupees ...
- Source: drugdu
- 90
- January 4, 2026
The “Cold” and “Hot” Sides of the Nuclear Medicine Trend

Nuclear medicine , once considered a “niche” field, is now rapidly entering the fast lane of pharmaceutical innovation. Novartis’ Pluvicto surpassed $1 billion in sales in just three years, not only demonstrating the enormous commercial potential of radiopharmaceuticals but also igniting the R&D enthusiasm of pharmaceutical companies worldwide. In China, driven by both favorable policies and technological innovation, the radiopharmaceutical market is transitioning from a period of stagnation to full-scale explosive growth. However, behind this seemingly prosperous track lie multiple challenges, such as target homogenization, tight supply of nuclides, and high technological barriers. 01 The rise of a multi-billion dollar industry Amidst the global wave of pharmaceutical innovation, radiopharmaceuticals are emerging at an astonishing pace, becoming a “new blue ocean” for capital and pharmaceutical companies. In 2023, the global radiopharmaceutical market reached $10.7 billion, and is projected to climb to $22.8 billion by 2030, representing a compound annual growth rate ...
- Source: drugdu
- 61
- January 4, 2026
D-2570 Demonstrates Excellent Efficacy in Phase II Clinical Trial for Moderate-to-Severe Plaque Psoriasis

Regarding the latest clinical progress of D-2570, InventisBio stated that the Phase III clinical trial for psoriasis is proceeding as scheduled. D-2570 is currently under clinical development for various autoimmune diseases, including psoriasis, ulcerative colitis, psoriatic arthritis, and systemic lupus erythematosus (SLE). In December 2025, results from a Phase II clinical study of D-2570 in treating moderate-to-severe plaque psoriasis were published in the Journal of the American Academy of Dermatology (JAAD, IF: 11.79), a top-tier international journal in dermatology. Data showed that after 12 weeks of treatment, D-2570 exhibited excellent efficacy, significantly outperforming the placebo group across all efficacy endpoints. The results indicated significant improvements in the severity and extent of skin lesions after a short treatment period, demonstrating D-2570’s ability to rapidly alleviate the disease burden for patients. Overall, D-2570 was well-tolerated, with most adverse events being mild to moderate and no serious adverse events (SAEs) reported. Its safety ...
- Source: drugdu
- 110
- January 4, 2026
IND Application for Targeted siRNA Drug FB7013 Accepted

Frontier Biotechnologies (688221) announced that on December 22, 2025, the company submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013. Developed in-house, FB7013 is a targeted siRNA drug designed to inhibit MASP-2, a key protein in the lectin pathway of the complement system. On December 31, 2025, the company received the official notice confirming that the application has been formally accepted. FB7013 injection is intended for the treatment of primary immunoglobulin A nephropathy (IgAN) and possesses first-in-class potential. According to preclinical data, FB7013 demonstrated potent and long-lasting inhibition of the target protein in healthy cynomolgus monkeys, achieving a maximum knockdown rate of over 95%. In IgAN models, FB7013 showed significant efficacy, with dose-dependent improvements in both total urinary protein and glomerular filtration rate (GFR), alongside a favorable safety profile. In the first three quarters of 2025, Frontier Biotechnologies reported a revenue of 103 ...
- Source: drugdu
- 63
- January 4, 2026
Boston Scientific has changed its leadership in its core business!

According to recent foreign media reports, Boston Scientific (NYSE: BSX) will see a major personnel change in its cardiac rhythm management and diagnostics (CRMDx) business in 2026. Scott Olson, Senior Vice President and President of the business unit, announced on LinkedIn that he plans to retire at the end of 2025. Scott Olson, who has worked at Boston Scientific for 27 years , will be succeeded by Angelo De Rosa in early 2026 after his retirement . Angelo De Rosa is also a seasoned veteran of Boston Scientific, having joined in 2014 as Vice President of Marketing. In recent years, he has led the company’s Watchman left atrial appendage occluder business with outstanding results. Furthermore, it is worth noting that upon taking office, Angelo De Rosa will not only lead the CRMDx business but will also join the Boston Scientific Executive Committee. Angelo De Rosa stated that his career at ...
- Source: drugdu
- 97
- January 2, 2026
China Biopharmaceutical’s innovative drug TQH3906 completes Phase II clinical trial.

On December 29, China Biopharmaceutical (01177) issued an announcement stating that the Group’s independently developed Class 1 innovative drug…TQH3906, a “TYK2/JAK1JH2 allosteric inhibitor,” has recently completed its Phase II clinical trial for moderate to severe plaque psoriasis. Results showed that all dose groups of TQH3906 demonstrated good safety and tolerability, and met the primary endpoint of the Phase II study. The study enrolled 209 patients, including a placebo group and five different TQH3906 dose groups, with oral administration once daily. In terms of efficacy, TQH3906 showed a good dose-response relationship. At the recommended phase 2 dose, after 12 weeks of treatment, the PASI75 response rate exceeded 90% and the PASI90 response rate exceeded 70%, which was significantly better than the PASI75 and PASI90 response rates in the placebo group (approximately 10% and 5%, respectively). In terms of safety, TQH3906 has a good overall safety profile, with the overall incidence of ...
- Source: drugdu
- 96
- January 2, 2026
Transcenta Group-B and EirGenix Reach Biopharmaceutical Manufacturing Collaboration Agreement

On December 29, Transcenta Holdings Group-B (06628) announced a strategic collaboration and non-exclusive technology licensing agreement with EirGenix. The agreement aims to advance integrated continuous flow manufacturing of biopharmaceuticals and improve global accessibility to affordable biopharmaceuticals. Under the agreement, the company will grant EirGenix a non-exclusive license to its highly integrated continuous flow bioprocess manufacturing (HiCB) platform and provide complete process documentation, core process technologies and experience, and regulatory support services. The company will receive a substantial upfront payment and milestone payments, and will be able to collect future royalties related to the commercialization of the licensed technology. This collaboration is expected to significantly reduce production costs, enabling patients worldwide to access high-quality, affordable biologics. EirGenix plans to use the HiCB platform for its biologics development programs and manufacturing operations, supporting CDMO customers seeking highly integrated continuous flow manufacturing solutions. https://finance.eastmoney.com/a/202512293604195792.html
- Source: drugdu
- 97
- January 2, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.